How much did Seagen achieve in EBIT for the current year?
In the current year, Seagen has achieved an EBIT of -426.67 M USD.
Seagen EBIT 2024
Seagen EBIT
-426.67 M USD
Ticker
SGEN
ISIN
US81181C1045
WKN
602322
In 2024, Seagen's EBIT was -426.67 M USD, a -49.11% increase from the -838.38 M USD EBIT recorded in the previous year.
The Seagen EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | 2 |
| 2027e | 1.45 |
| 2026e | 0.78 |
| 2025e | 0.12 |
| 2024e | -0.43 |
| 2023e | -0.84 |
| 2022 | -0.61 |
| 2021 | -0.68 |
| 2020 | 0.6 |
| 2019 | -0.22 |
| 2018 | -0.25 |
| 2017 | -0.2 |
| 2016 | -0.14 |
| 2015 | -0.12 |
| 2014 | -0.08 |
| 2013 | -0.06 |
| 2012 | -0.06 |
| 2011 | -0.14 |
| 2010 | -0.07 |
| 2009 | -0.08 |
| 2008 | -0.09 |
| 2007 | -0.06 |
| 2006 | -0.04 |
| 2005 | -0.03 |
| 2004 | -0.04 |
| 2003 | -0.02 |
Seagen Revenue, EBIT, Net Income US81181C1045 · 602322
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Seagen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Seagen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Seagen’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Seagen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Seagen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Seagen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Seagen’s growth potential.
Seagen Revenue, EBIT and net profit per share
| Date | Seagen Revenue | Seagen EBIT | Seagen Net Income |
|---|---|---|---|
| 2029e | 8.27 B undefined | 0 undefined | 2.22 B undefined |
| 2028e | 7.18 B undefined | 2 B undefined | 1.69 B undefined |
| 2027e | 6.32 B undefined | 1.45 B undefined | 1.28 B undefined |
| 2026e | 5.33 B undefined | 784.71 M undefined | 710.91 M undefined |
| 2025e | 4.28 B undefined | 115.42 M undefined | 117.38 M undefined |
| 2024e | 3.32 B undefined | -426.67 M undefined | -379.39 M undefined |
| 2023e | 2.51 B undefined | -838.38 M undefined | -801.48 M undefined |
| 2022 | 1.96 B undefined | -613 M undefined | -610.3 M undefined |
| 2021 | 1.57 B undefined | -682.1 M undefined | -674.5 M undefined |
| 2020 | 2.18 B undefined | 596.9 M undefined | 613.7 M undefined |
| 2019 | 916.7 M undefined | -220.5 M undefined | -158.7 M undefined |
| 2018 | 654.7 M undefined | -251.5 M undefined | -222.7 M undefined |
| 2017 | 482.3 M undefined | -195.8 M undefined | -125.5 M undefined |
| 2016 | 418.1 M undefined | -142.7 M undefined | -140.1 M undefined |
| 2015 | 336.8 M undefined | -121 M undefined | -120.5 M undefined |
| 2014 | 286.8 M undefined | -77.4 M undefined | -76.1 M undefined |
| 2013 | 269.3 M undefined | -62.9 M undefined | -62.5 M undefined |
| 2012 | 210.8 M undefined | -57.3 M undefined | -53.8 M undefined |
| 2011 | 94.8 M undefined | -144.4 M undefined | -152 M undefined |
| 2010 | 107.5 M undefined | -68.2 M undefined | -66.3 M undefined |
| 2009 | 52 M undefined | -84.9 M undefined | -81.7 M undefined |
| 2008 | 35.2 M undefined | -91.8 M undefined | -85.5 M undefined |
| 2007 | 22.4 M undefined | -55.6 M undefined | -48.9 M undefined |
| 2006 | 10 M undefined | -40.2 M undefined | -36 M undefined |
| 2005 | 9.8 M undefined | -32.1 M undefined | -29.4 M undefined |
| 2004 | 6.7 M undefined | -37.7 M undefined | -72 M undefined |
| 2003 | 5.1 M undefined | -23.3 M undefined | -22.3 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2003 | 5.1 M USD | -23.3 M USD | -22.3 M USD |
| 2004 | 6.7 M USD | -37.7 M USD | -72 M USD |
| 2005 | 9.8 M USD | -32.1 M USD | -29.4 M USD |
| 2006 | 10 M USD | -40.2 M USD | -36 M USD |
| 2007 | 22.4 M USD | -55.6 M USD | -48.9 M USD |
| 2008 | 35.2 M USD | -91.8 M USD | -85.5 M USD |
| 2009 | 52 M USD | -84.9 M USD | -81.7 M USD |
| 2010 | 107.5 M USD | -68.2 M USD | -66.3 M USD |
| 2011 | 94.8 M USD | -144.4 M USD | -152 M USD |
| 2012 | 210.8 M USD | -57.3 M USD | -53.8 M USD |
| 2013 | 269.3 M USD | -62.9 M USD | -62.5 M USD |
| 2014 | 286.8 M USD | -77.4 M USD | -76.1 M USD |
| 2015 | 336.8 M USD | -121 M USD | -120.5 M USD |
| 2016 | 418.1 M USD | -142.7 M USD | -140.1 M USD |
| 2017 | 482.3 M USD | -195.8 M USD | -125.5 M USD |
| 2018 | 654.7 M USD | -251.5 M USD | -222.7 M USD |
| 2019 | 916.7 M USD | -220.5 M USD | -158.7 M USD |
| 2020 | 2.18 B USD | 596.9 M USD | 613.7 M USD |
| 2021 | 1.57 B USD | -682.1 M USD | -674.5 M USD |
| 2022 | 1.96 B USD | -613 M USD | -610.3 M USD |
| 2023e | 2.51 B USD | -838.38 M USD | -801.48 M USD |
| 2024e | 3.32 B USD | -426.67 M USD | -379.39 M USD |
| 2025e | 4.28 B USD | 115.42 M USD | 117.38 M USD |
| 2026e | 5.33 B USD | 784.71 M USD | 710.91 M USD |
| 2027e | 6.32 B USD | 1.45 B USD | 1.28 B USD |
| 2028e | 7.18 B USD | 2 B USD | 1.69 B USD |
| 2029e | 8.27 B USD | 0 USD | 2.22 B USD |
Seagen stock margins US81181C1045 · 602322
The Seagen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Seagen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Seagen.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Seagen's sales revenue. A higher gross margin percentage indicates that the Seagen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Seagen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Seagen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Seagen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Seagen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Seagen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Seagen Margin History
| Seagen Gross margin | Seagen Profit margin | Seagen EBIT margin | Seagen Profit margin |
|---|---|---|---|
| 2029e | 79.11 % | 0 % | 26.82 % |
| 2028e | 79.11 % | 27.86 % | 23.52 % |
| 2027e | 79.11 % | 22.97 % | 20.25 % |
| 2026e | 79.11 % | 14.73 % | 13.34 % |
| 2025e | 79.11 % | 2.7 % | 2.74 % |
| 2024e | 79.11 % | -12.86 % | -11.43 % |
| 2023e | 79.11 % | -33.47 % | -32 % |
| 2022 | 79.11 % | -31.24 % | -31.1 % |
| 2021 | 80.21 % | -43.32 % | -42.84 % |
| 2020 | 89.99 % | 27.44 % | 28.21 % |
| 2019 | 95.21 % | -24.05 % | -17.31 % |
| 2018 | 86.51 % | -38.41 % | -34.02 % |
| 2017 | 88.76 % | -40.6 % | -26.02 % |
| 2016 | 89.88 % | -34.13 % | -33.51 % |
| 2015 | 88.9 % | -35.93 % | -35.78 % |
| 2014 | 89.85 % | -26.99 % | -26.53 % |
| 2013 | 92.13 % | -23.36 % | -23.21 % |
| 2012 | 93.6 % | -27.18 % | -25.52 % |
| 2011 | 96.73 % | -152.32 % | -160.34 % |
| 2010 | 100 % | -63.44 % | -61.67 % |
| 2009 | 100 % | -163.27 % | -157.12 % |
| 2008 | 79.11 % | -260.8 % | -242.9 % |
| 2007 | 79.11 % | -248.21 % | -218.3 % |
| 2006 | 79.11 % | -402 % | -360 % |
| 2005 | 79.11 % | -327.55 % | -300 % |
| 2004 | 79.11 % | -562.69 % | -1,074.63 % |
| 2003 | 79.11 % | -456.86 % | -437.25 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2003 | 79.11 % | -456.86 % | -437.25 % |
| 2004 | 79.11 % | -562.69 % | -1,074.63 % |
| 2005 | 79.11 % | -327.55 % | -300 % |
| 2006 | 79.11 % | -402 % | -360 % |
| 2007 | 79.11 % | -248.21 % | -218.3 % |
| 2008 | 79.11 % | -260.8 % | -242.9 % |
| 2009 | 100 % | -163.27 % | -157.12 % |
| 2010 | 100 % | -63.44 % | -61.67 % |
| 2011 | 96.73 % | -152.32 % | -160.34 % |
| 2012 | 93.6 % | -27.18 % | -25.52 % |
| 2013 | 92.13 % | -23.36 % | -23.21 % |
| 2014 | 89.85 % | -26.99 % | -26.53 % |
| 2015 | 88.9 % | -35.93 % | -35.78 % |
| 2016 | 89.88 % | -34.13 % | -33.51 % |
| 2017 | 88.76 % | -40.6 % | -26.02 % |
| 2018 | 86.51 % | -38.41 % | -34.02 % |
| 2019 | 95.21 % | -24.05 % | -17.31 % |
| 2020 | 89.99 % | 27.44 % | 28.21 % |
| 2021 | 80.21 % | -43.32 % | -42.84 % |
| 2022 | 79.11 % | -31.24 % | -31.1 % |
| 2023e | 79.11 % | -33.47 % | -32 % |
| 2024e | 79.11 % | -12.86 % | -11.43 % |
| 2025e | 79.11 % | 2.7 % | 2.74 % |
| 2026e | 79.11 % | 14.73 % | 13.34 % |
| 2027e | 79.11 % | 22.97 % | 20.25 % |
| 2028e | 79.11 % | 27.86 % | 23.52 % |
| 2029e | 79.11 % | 0 % | 26.82 % |
Seagen Aktienanalyse
What does Seagen do?
Seagen Inc is a pharmaceutical and biotech company specialized in the development of drugs for cancer treatment and supporting the health of patients with chronic diseases. The company was founded in 1997 and has its headquarters in Bothell, Washington. Seagen Inc's history began when the founders, Clay Siegall and H. Perry Fell, decided to establish a company focused on developing innovative technologies and biological solutions for fighting cancer. The company started with a small workforce and a focus on the development of antibodies against cancer cells. Over the years, Seagen has become a major player in the industry and has launched several successful drugs worldwide. Seagen Inc specializes in the development of cancer medications, including antibodies against cancer cells. The company strives to improve the effectiveness of cancer treatments and reduce the number of side effects. Its flagship products are Adcetris and Padcev, both used for the treatment of specific types of cancer. Adcetris (Brentuximab Vedotin) is an antibody-drug conjugate and the first of its kind approved worldwide for use against Hodgkin lymphomas and systemic anaplastic large cell lymphoma. It contains a special chemical that is bound to an antibody to directly attack cancer cells. Adcetris has proven to be very effective against lymphomas and is available on prescription in many countries. Padcev (Enfortumab Vedotin-ejfv) is another antibody-drug conjugate used for the treatment of bladder cancer. The drug has shown effectiveness in clinical studies and has been approved by the FDA to help patients who have no other treatment options. Padcev is being developed and marketed by Seagen in collaboration with Astellas Pharma. In addition to developing cancer medications, Seagen Inc is also involved in the research and development of technologies for autoimmune disease therapy. The company has developed a technology platform that has proven to be highly effective in the development of antibody-based therapies. This platform is used both internally and in partnerships with other pharmaceutical companies. Seagen Inc also leverages partnerships to expand its business globally and advance the development of new therapies. The company has entered into a strategic partnership with Takeda Pharmaceutical to support the development and commercialization of Adcetris. Additionally, Seagen Inc collaborates with various universities and research institutions to develop new technologies and treatment options. Overall, Seagen Inc has experienced strong growth in recent years and has become a major player in the biotech and pharmaceutical industry. The company remains committed to its mission of developing innovative technologies and solutions for fighting cancer and other chronic diseases. Seagen ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Seagen's EBIT
Seagen's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Seagen's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Seagen's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Seagen’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Seagen stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Seagen.
How has the EBIT of Seagen developed in recent years?
The EBIT of Seagen has increased by -49.108% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Seagen?
The EBIT of Seagen is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Seagen pay?
Over the past 12 months, Seagen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seagen is expected to pay a dividend of 0 USD.
What is the dividend yield of Seagen?
The current dividend yield of Seagen is .
When does Seagen pay dividends?
Seagen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Seagen?
Seagen paid dividends every year for the past 0 years.
What is the dividend of Seagen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Seagen located?
Seagen is assigned to the 'Health' sector.
Wann musste ich die Aktien von Seagen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Seagen from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Seagen pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Seagen in the year 2023?
In the year 2023, Seagen distributed 0 USD as dividends.
In which currency does Seagen pay out the dividend?
The dividends of Seagen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Seagen
Our stock analysis for Seagen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seagen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
